Over the past three years, End­points News has spot­light­ed 60 women who have blazed trails and su­per­charged R&D across the bio­phar­ma world. And judg­ing from the re­sponse we’ve re­ceived, to both our spe­cial re­ports and live events, telling their sto­ries — in­clud­ing any ob­sta­cles they may have had to over­come — has in­spired our read­ers in many dif­fer­ent ways.

But change takes time, and the fact re­mains that women are still un­der­rep­re­sent­ed at the up­per ranks of the drug-mak­ing world.

We are con­tin­u­ing with our an­nu­al tra­di­tion of putting to­geth­er a spe­cial re­port to rec­og­nize the grow­ing num­ber of en­ter­pris­ing women who are mak­ing waves in bio­phar­ma R&D.

They may all have dif­fer­ent views on is­sues and tack­le gen­der di­ver­si­ty dif­fer­ent­ly. They may al­so come from di­verse ge­o­graph­ic or eth­nic back­grounds. But they are in­creas­ing­ly speak­ing up: Af­ter Roe v. Wade was over­turned ear­li­er this year, women across the in­dus­try have led the fight for in­creased ac­cess to re­pro­duc­tive care.

Women and those in mi­nor­i­ty groups make up just 14% of board mem­bers at pub­lic mi­cro- and small-cap com­pa­nies, ac­cord­ing to a re­cent re­port by the Bed­ford Group and Transearch. And when it comes to board chairs, they rep­re­sent just 5.7% and 4.3%, re­spec­tive­ly.

Our lists are nev­er meant to be ex­haus­tive. Rather, we hope they will serve as a col­lec­tion of snap­shots in time, por­traits that will both hon­or and com­mem­o­rate the con­tri­bu­tions these women have made to the cre­ation of new med­i­cines.

So tell us about your CEOs, CMOs, CSOs, R&D di­rec­tors and the like who have left an im­pres­sion at your work­place, or at any oth­er firm with­in the in­dus­try. Their for­mal roles mat­ter less than the im­pact they’ve brought.

You may fill in the nom­i­na­tion form here or be­low. Al­ter­na­tive­ly, you can email your nom­i­na­tions to us at nicole@end­pointsnews.com and am­ber@end­pointsnews.com. Nom­i­na­tions close on Aug. 29, and our spe­cial re­port will run lat­er this year.

We look for­ward to meet­ing all of them.

Cre­ate your own user feed­back sur­vey

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.

The White House’s Office of Science and Technology Policy (OSTP) last year sought to find ways to better coordinate large-scale clinical trials in the US — as the UK lead by example during the pandemic — especially for these emergency clinical trials.

The lobbying group PhRMA Tuesday called for more clinical trial diversity in underserved areas, including by making participation less of a burden, and expanding eligibility criteria when appropriate.